Introduction

41
Cancer is responsible for one in every four deaths in the USA and 42 is still not effectively managed therapeutically [1] . The current 43 paradigm of chemotherapy and surgery requires improvements so 44 as to enhance the overall survival rate of cancer patients and to limit 45 the toxic side effects of the current chemotherapeutic approaches. given the field of cancer immunotherapy a further boost [5] .
57
The delivery of a cancer vaccine through the use of nano-and 58 microparticle-based vectors is showing promise in both clinical 59 and preclinical settings [6] . (Fig. 4) . were measured in sera using ELISA (as described in Materials and methods). All groups were compared using ANOVA followed by Tukey's post-test ( ⁄ p < 0.01). The CPTEG:CPH/OVA CpG group showed significantly higher serum titers for IgG 1 when compared with all groups. Fig. 4 . Analysis of OVA-specific T cell frequency in PBLs of mice vaccinated with different CPTEG:CPH microparticle formulations. Mice were primed (day 0) and boosted (day 7) with the indicated formulations. PBLs were stained using a fluorescently tagged tetramer, designed to bind to OVA-specific CD8 + T cells, on day 14 (i) and day 20 (ii) post-primary vaccination with the indicated microparticle formulations. All groups were compared statistically using ANOVA followed by Tukey's post-test ( 
Conclusions
373
To date, the use of biodegradable microparticles in tumor 374 immunotherapy has primarily involved PLGA microparticles [6] . 375 Here, microparticles composed of the bioerodible amphiphilic poly- 
